<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>)/spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:hpo ids='HP_0002503'>spinocerebellar degeneration</z:hpo>, for which there is no effective treatment </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: This study involved the clinical response of lamotrigine (LTG) on six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients with early <z:hpo ids='HP_0002078'>truncal ataxia</z:hpo> and the effect of LTG on the alteration of ataxin-3 expression in the transformed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> lymphoblastoid cells </plain></SENT>
<SENT sid="2" pm="."><plain>RESULT: LTG medication was found, on the basis of single leg standing test tandem gait index, to effectively improve gait balance, but did not prove to be effective in the withdrawal period </plain></SENT>
<SENT sid="3" pm="."><plain>In Western blot analysis of ataxin-3 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> lymphoblastoid cells, extracellular application of LTG, while leaving the <z:mpath ids='MPATH_458'>normal</z:mpath> level of ataxin-3 intact, decreased the expression of mutant ataxin-3 in a dose-related manner </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: Our results indicated that LTG may have significant benefits in relief of <z:hpo ids='HP_0001288'>gait disturbance</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients with early <z:hpo ids='HP_0001251'>ataxia</z:hpo>, and may be related to the decreased expression of mutant ataxin-3 </plain></SENT>
</text></document>